Objective-The metabolic syndrome (MetS) may contribute to the pathogenesis of venous thromboembolism (VTE), but this association requires additional investigation. Approach and Results-We performed a patient-level meta-analysis of case-control and cohort studies that evaluated the role of MetS and risk of unprovoked VTE. For case-control studies, odds ratios and 95% confidence intervals were calculated using logistic regression analysis to estimate the influence of individual variables on the risk of VTE; χ 2 tests for trend were used to investigate the effect of increasing number of components of MetS on the risk of VTE and to explore the influence of abdominal obesity on this relationship. For cohort studies, hazard ratios and 95% confidence interval were calculated using multivariable Cox regression analysis. Six case-control studies were included (908 cases with unprovoked VTE and 1794 controls): in multivariate analysis, MetS was independently associated with VTE (odds ratio, 1.91; 95% confidence interval, 1.57-2.33), and both MetS and abdominal obesity were better predictors of unprovoked VTE than obesity defined by the body mass index. Two prospective cohort studies were included (26 531 subjects and 289 unprovoked VTE events): age, obesity, and abdominal obesity, but not MetS were associated with VTE. Conclusions-Case-control but not prospective cohort studies support an association between MetS and VTE. Abdominal adiposity is a strong risk factor for VTE. 
V enous thromboembolism (VTE) is a multifactorial disease that can affect apparently healthy individuals and hospitalized patients. In most cases, the occurrence of VTE is associated with the presence of major provoking factors, such as a recent surgical procedure, trauma, fracture, pregnancy or puerperium, the use of oral contraceptives, prolonged immobilization, or a severe medical disease. 1 However, in ≤45% of cases, none of these risk factors is identified and VTE remains classified as unprovoked. [1] [2] [3] During recent years, several studies have reported an increased risk of cardiovascular events in patients with VTE. [4] [5] [6] [7] [8] [9] The results of a recent meta-analysis reported that the overall risk of cardiovascular events, as well as the risk of acute myocardial infarction or stroke after VTE, is significantly higher in patients with unprovoked VTE than in patients with VTE secondary to a major provoking factor. 9 One of the hypotheses for this association between cardiovascular disease and VTE is that the 2 diseases may share common risk factors. Among traditional cardiovascular risk factors, obesity and age have been demonstrated to be consistently independent risk factors also for VTE. 10, 11 In a systematic review of the literature and meta-analysis, we found that arterial hypertension, diabetes mellitus, and dyslipidemia are also associated with VTE. 12 Although the estimated odds ratios (ORs) for these variables were less robust than those reported for established major risk factors for VTE, such as cancer or surgery, the findings are relevant because cardiovascular risk factors are more common, often coexist and their coexistence, at least for atherosclerotic disorders, is associated with an additive causative effect.
The metabolic syndrome is a cluster of cardiovascular risk factors, including abdominal obesity, hypertension, insulin resistance, and dyslipidemia, with high triglycerides levels and low high-density lipoprotein cholesterol. 13 The interaction of these risk factors results in a significantly increased risk of developing coronary artery disease and ischemic stroke. 14 Recent studies suggest that the metabolic syndrome may also be associated with VTE, [15] [16] [17] [18] [19] [20] [21] but several issues remain unclear. In particular, whether this association is attributable to the metabolic syndrome or to abdominal obesity alone, with no additional contribution by the other components, and whether this association is sex specific remain to be established. 19, 20 To explore these issues further, we performed a systematic search of the literature and an individual patient-level meta-analysis of published studies, evaluating the association between unprovoked VTE and the metabolic syndrome.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
The results of study search and selection process are summarized in Figure 1 . The interobserver agreement for the study selection was excellent, with a κ of 0.92 . After the selection  process, 8 studies were eligible for this analysis,  15,17-23 6 were  case-control studies,  15,17,18,21-23 and 2 were prospective cohort studies. 19, 20 All contacted investigators agreed to provide their full database of the study. Table 1 summarizes the characteristics of the 6 case-control studies included in the analysis, and Table 2 summarizes the characteristics of the 2 prospective cohort studies. Briefly, among case-control studies, 1 study included patients with deep vein thrombosis only, 15 whereas the remaining studies included patients with both deep vein thrombosis and pulmonary embolism. 17, 18, [21] [22] [23] Five studies enrolled patients with a single episode of VTE, 15, 18, [21] [22] [23] and 1 study enrolled patients with recurrent VTE. 17 One study was conducted in Asian patients only, 18 and the other 5 studies enrolled white patients. 15, 17, [21] [22] [23] Mean age of study patients in case-control studies was <50 years in 4 studies, 17, 18, 21, 22 between 50 and 60 years in 1 study, 23 and >60 years in 1 study. 15 According to our predefined quality score for case-control studies, 2 studies scored 6, thus were high quality, 18, 22 4 studies scored 5, thus were medium quality. 15, 17, 21, 23 According to our predefined quality score for cohort studies, both studies scored 6 and were thus high quality. 19, 20 In prospective cohort studies, the mean time elapsed between the measurement of the features of the metabolic syndrome and VTE events was 7.6 years (range, 0.6-15.1) 19 in one study and 6.7 years (range, 0.2-12.7 years) in the second study. 20 Information was collected on both deep vein thrombosis and pulmonary embolism. 19, 20 At baseline, mean age of study subjects was 58 years in one study 19 and between 60 and 63 years (metabolic syndrome negative and positive patients, respectively) in the second study. 20 The definition of unprovoked VTE slightly differed among all selected studies (Tables 1 and 2 
Results of the Analysis of Case-Control Studies
We initially analyzed aggregate data, and the presence of the metabolic syndrome was significantly associated with VTE with an OR of 2.64 (95% confidence interval [CI], 2.19-3.18). There was no heterogeneity among the studies (I 2 =0%; Figure 2 ). We subsequently performed the patient-level analysis. Overall, we received data for 908 patients with unprovoked VTE and 1794 controls. No cases or controls were excluded from the analysis for insufficient data. Baseline characteristics of the 2702 cases and controls enrolled in this study are summarized in Table 3 . The 2 groups were significantly different according to sex, mean age, and the prevalence of obesity. Dyslipidemia was significantly more prevalent in cases of unprovoked VTE than in controls. The metabolic syndrome and each of its components were also significantly more prevalent in the group of cases than controls. In our subgroup analyses, the OR for VTE for metabolic syndrome in men was 1.88 (95% CI, 1.46-2.42) and in women was 2.77 (95% CI, 2.16-3.56). The OR for VTE with metabolic syndrome in patients <50 years was 1.99 (95% CI, 1.57-2.53), and in patients aged ≥50 years was 2.07 (95% CI, 1.61-2.66). Heterogeneity between male and female patients was significant (χ 2 4.63; P for interaction, 0.03), whereas there was no statistically significant difference according to age (P for interaction >0.10).
In multivariate logistic regression analysis, the metabolic syndrome remained associated with odds of VTE after adjusting for age, sex, and obesity, with an OR of 1.91 (95% CI, 1.57-2.33; Table 4 ).
The analysis was repeated after the exclusion of the study by Ay et al 17 because it was the only study including patients with recurrent VTE only. The results were unchanged (data not shown, available on request). The association between the metabolic syndrome and VTE was significant both in male and in female patients (OR, 1.61; 95% CI, 1.22-2.20 and OR, 2.32; 95% CI, 1.74-3.09, respectively) after adjusting for age and obesity. The observed association remained statistically significant when the multivariate analysis was repeated after the exclusion of patients with increased waist circumference with an OR of 2.19 (95% CI, 1.51-3.16) after adjusting for age and obesity.
Results of multiadjusted regression models on the association of the individual components of the metabolic syndrome and VTE are reported in Table 4 .
Results of the Analysis of Prospective Cohort Studies
We initially analyzed aggregate data, and the presence of the metabolic syndrome was significantly associated with VTE, with an OR of 1.15 (95% CI, 0.90-1.47). There was no heterogeneity among the studies (I 2 =0%; Figure 3 ). We subsequently performed the patient-level analysis. Overall, we received data on 26 544 subjects who had 552 VTE events during follow-up. Excluding 13 subjects with incomplete data and considering only unprovoked events, 26 531 participants had 289 events during follow-up.
Baseline characteristics of patients who developed and who did not develop unprovoked VTE during follow-up are summarized in Table 5 . The 2 groups were significantly different according to mean age, prevalence of obesity, abdominal obesity, and hypertension, whereas other baseline characteristics and prevalence of metabolic syndrome were similar in the 2 groups. ‡White patients: waist circumference >102 cm for men and >88 cm for women; Asian patients: waist circumference >90 cm for men and >80 cm for women. In the random effects Cox model age ≥65 years (hazard ratio, 1.80; 95% CI, 1.39-2.34), obesity (hazard ratio, 1.56; 95% CI, 1.15, 2.11) and abdominal obesity (hazard ratio, 1.55; 95% CI, 1.15, 2.08) were significantly associated with the development of unprovoked VTE during follow-up, whereas hypertension was not (hazard ratio, 1.12; 95% CI, 0.86-1.46). The metabolic syndrome was not significantly associated with an increased risk of developing VTE when added to a multivariate model with obesity and age ≥65 years. The metabolic syndrome was also not significantly associated with an increased risk of VTE in a multivariate model that included all other covariates that were significantly associated with VTE in univariate analysis or considering the prespecified subgroups according to age and sex (data not shown). Given the absence of association between the metabolic syndrome and VTE, no further analysis on the additive role of the individual components was performed.
Discussion
The results of this patient-level meta-analysis do not convincingly support the role of the metabolic syndrome as an independent risk factor for VTE but support the role of abdominal adiposity, as assessed by waist circumference, as a strong risk factor for VTE. The association between the metabolic syndrome and unprovoked VTE was confirmed in the analysis of case-control studies in different patient subgroups but not in the analysis of prospective cohort studies. Likewise, individual components of the metabolic syndrome were also independently associated with VTE, and their coexistence resulted in an additive effect in case-control studies, but not in longitudinal studies, with the exception of abdominal obesity.
The fact that the importance of the coclustering of the various components of the metabolic syndrome or their complete expression did not play a role in prospective studies on VTE occurrence may suggest a minor contribution of the atherogenic pattern found in the metabolic syndrome to the pathogenesis of VTE. Conversely, the state of chronic, low-grade inflammation that is associated with the metabolic syndrome, but that most of all depends on the presence of abdominal adiposity, may result in a prothrombotic state that predisposes to VTE. Both chronic inflammation and insulin resistance, which plays a key role in the pathogenesis of the syndrome, are associated with increased levels of fibrinogen, and low-grade chronic inflammation has also been associated with increased release of soluble tissue factor and factor VII. 24 The simultaneous increase in both soluble tissue factor and factor VII clearly enhances the risk of activation of the coagulation cascade. Furthermore, increased levels of plasminogen activator inhibitor-1 and decreased plasma tissue-type plasminogen activator activity are common in these patients, thus leading to a hypofibrinolytic state. 24 Recent studies have shown that plasminogen, thrombin-activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1, and tissue plasminogen activator are all associated with the risk of venous thrombosis, thus supporting the potential relevance of hypofibrinolysis as a link between VTE and both abdominal obesity and the metabolic syndrome. 25 Furthermore, hypofibrinolysis was also reported to be associated with an increased risk of recurrent VTE. 26 Taken together, these coagulation abnormalities have the potential to predispose patients to an increased risk of VTE. This hypothesis was initially suggested by the results of case-control studies, [15] [16] [17] [18] [21] [22] [23] and to a much lesser extent, by the results of prospective cohort studies. 19, 20 In fact, the main finding of 1 of the 2 longitudinal studies, the Tromso study, was that abdominal obesity is a necessary component for the association between the metabolic syndrome and VTE because after the removal of abdominal obesity this association is lost. This observation, substantially confirmed by the results of the present study, is relevant because abdominal adipose tissue, which is best viewed as an endocrine organ, 27 plays a central role in the cause of the metabolic syndrome and in predisposing to the . †White patients: waist circumference >102 cm for men and >88 cm for women; Asian patients: waist circumference >90 cm for men and >80 cm for women.
‡Patients currently receiving drug therapy for hypertension, diabetes mellitus, or dyslipidemia (only statins) were defined as having those disorders. chronic inflammatory state. For this reason, the International Diabetes Federation proposed the presence of abdominal obesity as a necessary condition for the diagnosis of the metabolic syndrome. 28 In the second longitudinal study, the LITE (Longitudinal Investigation of Thromboembolism Etiology) study, this finding was observed in men only. 20 In this study, abdominal obesity, but not the metabolic syndrome, was related to VTE in women. In men, the metabolic syndrome was associated with VTE, but when abdominal obesity was removed, this association between the metabolic syndrome and VTE was no longer statistically significant. Sex-related differences have been reported by some authors also for the association between the metabolic syndrome and the cardiovascular disease, 29, 30 but have not been confirmed by other studies, and the mechanisms underlying this finding have not been elucidated. The results of our individual patient data meta-analysis of case-control studies confirmed a statistically significant interaction by sex, but, differently from the study by Steffen et al, 20 the association between the metabolic syndrome and VTE, with or without abdominal obesity, remained significant in both men and women. This association could not be confirmed when the individual patients data of the 2 prospective cohort studies were analyzed.
The reasons for the observed discrepancies are, at least in part, attributable to the study designs. In the case-control studies included in our meta-analysis, the components of the metabolic syndrome were measured within 6 months after VTE in 4 studies, 15, 18, 21, 22 and after a median of 2.5 years and 60 months in 2 studies. 17, 23 In the longitudinal studies, the features of the metabolic syndrome were measured at baseline and VTE events occurred after years. 19, 20 Because all components of the metabolic syndrome are modifiable, and individuals with a higher cardiovascular risk profile at baseline may have been managed more aggressively, there is a chance that the effect of some of the metabolic risk factors may have been diluted at the time of the VTE event. Regular physical activity and a healthy diet are key elements for the primary intervention in patients with the metabolic syndrome and have been shown to reduce the incidence of VTE in some 31, 32 but not in all studies. 33, 34 Likewise, statins are among the main therapeutic strategies in patients with the metabolic syndrome and have also been recently shown to reduce the risk of VTE. 35 Another potential explanation for the observed discrepancies is that the prevalence of the metabolic syndrome increases with increasing age, 36, 37 and the distribution of risk factors may have changed in longitudinal studies during time between patients who subsequently developed VTE and patients without VTE. Of note, in 4 of the 5 case-control studies, 17, 18, 21, 22 the mean age of study patients ranged between 41 and 47 years, and only in 1 study the mean age of patients with VTE was 63 years. 15 Conversely, the mean age at baseline in the 2 prospective cohort studies was ≈60 years, 19, 20 and, thus VTE occurred in these studies at an older age when compared with the case-control studies. However, in the case-control studies, we separately assessed the association between the metabolic syndrome and the VTE in patients aged ≤50 years and in patients ≥50 years; this association remained statistically significant in both groups and the magnitude of the association was actually greater in older patients. Finally, a third explanation of the discrepancy between study designs is that the retrospective nature of case-control studies may have contributed to overestimation of the magnitude of the observed associations. In addition, also the time elapsed between VTE and the measurement of the components of the metabolic syndrome in the case-control studies included in our analysis might have contributed to bias because obesity is a known ‡White patients: waist circumference >102 cm for men and >88 cm for women; Asian patients: waist circumference >90 cm for men and >80 cm for women.
risk factor for VTE and weight loss counseling after VTE in overweight individuals might have been proposed to at least some of the patients. However, reduced mobility after acute VTE may have favored weight gain with consequent increased waist circumference and changes in lipid profile, thus resulting in a revers association.
There are several limitations to our study. First, inclusion criteria and the definition of unprovoked VTE differed among studies. When the analysis was repeated for case-control studies with the exclusion of the study that used different inclusion criteria (patients with recurrent VTE as opposed to patients with a first episode), 17 the results were unchanged. With regard to the different definitions of unprovoked VTE, these mainly related to the inclusion of hormone-associated VTE in 2 studies 17, 21 and of long-distance travel in another study. 22 However, both hormone-therapy and long-distance travel are considered as weak risk factors for VTE, and it is unlikely that the low number of patients included with either one of these risk factors may have significantly affected our results. Second, one of the studies was only performed in Asian patients. To reduce the potential bias of ethnical differences, we used ethnic-specific definitions of obesity and components of the metabolic syndrome. 38, 39 In conclusion, only the individual patient data meta-analysis of case-control studies confirmed an association between unprovoked VTE and the metabolic syndrome. This association was not present in longitudinal studies. Conversely, the meta-analysis of both case-control and longitudinal studies supports the role of abdominal adiposity as a strong risk factor for VTE. The modifiable nature of the individual components of the metabolic syndrome, but also bias that are intrinsic in the design of case-control studies, may explain this discrepancy. Additional studies that are specifically designed to address this issue taking into account all potential sources of bias are warranted. Furthermore, the role of the metabolic syndrome in the pathogenesis of VTE secondary to traditional major risk factors should also be explored.
